LOS ANGELES, July 22 (Reuters) - Roche Holding AG's Genentech Inc AstraZeneca Plcs's man in that
deal, since he was entitled to more than $145 million, mostly from the vesting
of stock options.
AstraZeneca had offered bonuses to MedImmune staff if they stayed on for a
minimum of a year.
(Editing by Toni Reinhold) Keywords: GENENTECH VENTURECAPITAL
tf.TFN-Europe_newsdesk@thomson.com
ak
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|